Rentosertib Trend 2026

Rentosertib is an investigational, selective inhibitor of the WEE1 kinase, a key regulator of the cell cycle and DNA damage repair. By blocking this enzyme, it disrupts cancer cells’ ability to fix DNA breaks, making them more vulnerable to chemotherapy or radiation. This targeted therapy is primarily being studied in clinical trials for advanced solid tumors, including ovarian and gastric cancers, offering a potential precision option for patients with limited alternatives.